Bioxcel Therapeutics' 15min chart triggers MACD Death Cross, KDJ Death Cross.

Bioxcel Therapeutics's 15-minute chart has triggered a MACD Death Cross and KDJ Death Cross at 09/11/2025 15:15. This indicates that the stock price has the potential to continue declining, and the momentum of the stock price is shifting towards the downside, suggesting a further decrease in value.

NEW HAVEN, Conn. — BioXcel Therapeutics, Inc. (NASDAQ: BTAI) has reported positive topline exploratory efficacy data from its SERENITY At-Home Phase 3 trial, which demonstrated continued effects and consistent benefits with repeat dosing of its proprietary sublingual film formulation, BXCL501 BioXcel reports positive efficacy data for at-home agitation treatment^[1]. However, the company's stock has experienced a significant technical setback, with a MACD Death Cross and KDJ Death Cross at 09/11/2025 15:15 BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia^[2].

The SERENITY At-Home trial evaluated the 120 mcg dose of BXCL501, marketed as IGALMI®, for the treatment of agitation associated with bipolar disorders or schizophrenia in an at-home setting. The trial, which was not powered for efficacy assessments, showed that BXCL501 demonstrated a significant mean reduction in modified Clinical Global Impression–Severity (mCGI-S) scores compared to placebo at two hours across 2,433 treated episodes (p.05) BioXcel reports positive efficacy data for at-home agitation treatment^[1]. Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across all severity levels of agitation episodes (p.0001) BioXcel reports positive efficacy data for at-home agitation treatment^[1].

Despite these positive results, the company's stock has been volatile, with prices ranging from $1.17 to $13.36 over the past 52 weeks BioXcel reports positive efficacy data for at-home agitation treatment^[1]. The technical indicators suggest a potential downward trend, with the MACD Death Cross and KDJ Death Cross indicating a shift in momentum towards the downside. This technical setback could be attributed to various factors, including market sentiment, investor expectations, and broader market conditions.

BioXcel Therapeutics plans to submit a supplemental New Drug Application (sNDA) in the first quarter of 2026 to expand IGALMI's usage to outpatient settings without healthcare provider supervision. The company estimates the total addressable market at 57-77 million agitation episodes annually, significantly higher than previous estimates of 23 million episodes per year BioXcel reports positive efficacy data for at-home agitation treatment^[1]. However, the company generated revenue of just $0.87 million in the last twelve months, with analysts anticipating a slight sales decline in the current year BioXcel reports positive efficacy data for at-home agitation treatment^[1].

While the positive trial results provide a potential catalyst for growth, the technical challenges faced by the stock may require investors to reassess their positions. Investors should closely monitor the company's financial health and growth potential, as well as the broader market conditions, to make informed investment decisions. For deeper insights into BioXcel's financial health and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro BioXcel reports positive efficacy data for at-home agitation treatment^[1].

In other recent news, BioXcel Therapeutics announced that its SERENITY At-Home Phase 3 trial met its primary safety endpoint, with the 120 mcg dose of BXCL501 well-tolerated with no discontinuations due to tolerability issues BioXcel reports positive efficacy data for at-home agitation treatment^[1]. The company plans to submit a supplemental New Drug Application in the first quarter of 2026 to expand IGALMI's usage to outpatient settings without healthcare provider supervision. The trial’s database lock has been completed, and the company expects to release topline results later this month, having collected data from over 2,600 agitation episodes across more than 200 patients. BioXcel has also scheduled an investor call to present these topline data. The trial results support a planned label expansion for IGALMI, aiming to broaden its application beyond medically supervised settings.